Multiple groups have shown that Aurora-A kinase can contribute to EGFR inhibitor resistance through activation of NF-κB in several cancers.18,33,34 However, we found that treatment of FaDu cells with Alisertib, an Aurora-A inhibitor, could not abolish Gefitinib induction of NF-κB (Supplementary Figure 8). This evidence concerns the gene NFKB1 and cancer.